458 Weekly paclitaxel plus trastuzumab in metastatic breast cancer (MBC): a multicentre German trial

John, Matthias; Hindenburg, Hans-Joachim; Hinke, Axel; Kriebel-Schmitt, R.; Papke, Jens; Stauch, Martina

doi:10.1016/s1359-6349(03)90490-3

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small, phase II trials that have evaluated trastuzumabtaxane combinations as first-line therapy in MBC have reported response rates of 50%-70% for trastuzumab in combination with docetaxel [29 -31], and 62%-81% for trastuzumab in combination with paclitaxel [32][33][34][35]. Two larger, randomized, phase II multicenter trials have corroborated an advantage of adding trastuzumab to a taxane as first-line therapy in patients with HER-2-positive MBC ( Table 1).…”

Section: Phase IImentioning

confidence: 99%

Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast Cancer

Bullock

Blackwell

2008

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Evaluate the results of trials assessing the efficacy of monotherapy and doublet therapy of the taxanes, paclitaxel and docetaxel, plus trastuzumab in HER-2-positive MBC patients.2. Administer the optimal dosing schedule of taxanes in HER-2-positive MBC patients.3. Explain the possible benefits and toxicity of using anthracycline-sparing platinum chemotherapy in combination with taxane-trastuzumab therapy for HER-2-positive MBC.This article is available for continuing medical education credit at CME.TheOncologist.com. In one study, the addition of carboplatin to paclitaxeltrastuzumab therapy resulted in a higher response rate and longer progression-free survival time; in the second study, the docetaxel-trastuzumab and docetaxel-trastuzumab-carboplatin combinations were equally effective. Ongoing correlative studies of taxanes, as well as newer formulations such as nanoparticle albuminCorrespondence: Kimberly L. CME CME ABSTRACT

show abstract

Section: Phase IImentioning

confidence: 99%

Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast Cancer

Bullock

Blackwell

2008

The Oncologist

View full text Add to dashboard Cite

show abstract

Trastuzumab

Plosker¹,

Keam²

2006

Drugs

104

View full text Add to dashboard Cite

Trastuzumab (Herceptin) is a humanised monoclonal antibody used in the treatment of breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2), which is associated with clinically aggressive disease and a poor prognosis. The addition of intravenous trastuzumab to first-line chemotherapy improved the time to disease progression, objective response rate, duration of response, and overall survival in randomised, multicentre trials in women with HER2-positive metastatic breast cancer. As such, trastuzumab has become the standard of care in this setting, despite its high acquisition cost and potential for cardiac events, and is licensed for use in combination with paclitaxel (Europe and the US) or docetaxel (Europe). In addition, trastuzumab monotherapy is approved for use in patients with HER2-positive metastatic breast cancer who have previously received chemotherapy for their metastatic disease. Recent data from large phase III trials with trastuzumab in the adjuvant setting revealed significant improvements in disease-free and overall survival. Thus, trastuzumab is also rapidly becoming a standard component of adjuvant therapy for patients with HER2-positive early-stage breast cancer.

show abstract

Cardiac Toxicity of Trastuzumab-Related Regimens in HER2-Overexpressing Breast Cancer

Ewer

O’Shaughnessy

2007

Clinical Breast Cancer

View full text Add to dashboard Cite

458 Weekly paclitaxel plus trastuzumab in metastatic breast cancer (MBC): a multicentre German trial

Cited by 3 publications

References 0 publications

Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast Cancer

Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast Cancer

Trastuzumab

Cardiac Toxicity of Trastuzumab-Related Regimens in HER2-Overexpressing Breast Cancer

Contact Info

Product

Resources

About